Comments
Loading...

Veracyte Analyst Ratings

VCYTNASDAQ
Logo brought to you by Benzinga Data
$29.92
-0.20-0.66%
Pre-Market: 4:40 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$51.00
Lowest Price Target1
$28.00
Consensus Price Target1
$41.90

Veracyte Analyst Ratings and Price Targets | NASDAQ:VCYT | Benzinga

Veracyte Inc has a consensus price target of $41.9 based on the ratings of 11 analysts. The high is $51 issued by Needham on February 25, 2025. The low is $28 issued by Morgan Stanley on November 18, 2024. The 3 most-recent analyst ratings were released by Stephens & Co., Craig-Hallum, and UBS on March 26, 2025, March 20, 2025, and February 25, 2025, respectively. With an average price target of $46.33 between Stephens & Co., Craig-Hallum, and UBS, there's an implied 54.86% upside for Veracyte Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
1
Dec 24
1
Jan
3
Feb
2
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.5
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Stephens & Co.
Craig-Hallum
UBS
Guggenheim
Needham

1calculated from analyst ratings

Analyst Ratings for Veracyte

Buy NowGet Alert
03/26/2025Buy Now50.4%Stephens & Co.
Mason Carrico41%
$45 → $45ReiteratesOverweight → OverweightGet Alert
03/20/2025Buy Now50.4%Craig-Hallum
John Wilkin26%
→ $45Initiates → BuyGet Alert
02/25/2025Buy Now63.77%UBS
Lu Li15%
$46 → $49MaintainsBuyGet Alert
02/25/2025Buy Now50.4%Guggenheim
Subbu Nambi43%
$45 → $45ReiteratesBuy → BuyGet Alert
02/25/2025Buy Now70.45%Needham
Mike Matson57%
$51 → $51ReiteratesBuy → BuyGet Alert
01/29/2025Buy Now70.45%Needham
Mike Matson57%
$44 → $51MaintainsBuyGet Alert
12/05/2024Buy Now23.66%Goldman Sachs
Matthew Sykes66%
$38 → $37DowngradeBuy → NeutralGet Alert
11/18/2024Buy Now-6.42%Morgan Stanley
Tejas Savant50%
$26 → $28MaintainsUnderweightGet Alert
11/08/2024Buy Now47.06%Scotiabank
Sung Ji Nam47%
$40 → $44MaintainsSector OutperformGet Alert
11/07/2024Buy Now27.01%Goldman Sachs
Matthew Sykes66%
$34 → $38MaintainsBuyGet Alert
11/07/2024Buy Now53.74%UBS
Lu Li15%
$43 → $46MaintainsBuyGet Alert
11/07/2024Buy Now47.06%Needham
Mike Matson57%
$37 → $44MaintainsBuyGet Alert
10/17/2024Buy Now33.69%Leerink Partners
Puneet Souda57%
$35 → $40MaintainsOutperformGet Alert
10/16/2024Buy Now43.72%UBS
Lu Li15%
→ $43Initiates → BuyGet Alert
10/10/2024Buy Now33.69%Guggenheim
Subbu Nambi43%
→ $40Initiates → BuyGet Alert
08/28/2024Buy Now23.66%Needham
Mike Matson57%
$31 → $37MaintainsBuyGet Alert
08/12/2024Buy Now-13.1%Morgan Stanley
Tejas Savant50%
$21 → $26MaintainsUnderweightGet Alert
08/07/2024Buy Now3.61%Needham
Mike Matson57%
$27 → $31MaintainsBuyGet Alert
05/08/2024Buy Now-9.76%Needham
Mike Matson57%
$33 → $27MaintainsBuyGet Alert
04/15/2024Buy Now-6.42%Goldman Sachs
Matthew Sykes66%
$32 → $28MaintainsBuyGet Alert
02/26/2024Buy Now-29.81%Morgan Stanley
Tejas Savant50%
$22 → $21MaintainsUnderweightGet Alert
02/23/2024Buy Now10.29%Needham
Mike Matson57%
$30 → $33MaintainsBuyGet Alert
11/10/2023Buy Now-26.47%Morgan Stanley
Tejas Savant50%
$23 → $22MaintainsUnderweightGet Alert
11/08/2023Buy Now0.27%Needham
Mike Matson57%
$35 → $30MaintainsBuyGet Alert
10/23/2023Buy Now6.95%Goldman Sachs
Matthew Sykes66%
$37 → $32MaintainsBuyGet Alert
10/20/2023Buy Now6.95%Goldman Sachs
Matthew Sykes66%
$37 → $32MaintainsBuyGet Alert
10/10/2023Buy Now13.64%Stephens & Co.
Mason Carrico41%
→ $34ReiteratesOverweight → OverweightGet Alert
08/09/2023Buy Now-23.13%Morgan Stanley
Tejas Savant50%
$22 → $23MaintainsUnderweightGet Alert
08/09/2023Buy Now16.98%Needham
Mike Matson57%
$34 → $35MaintainsBuyGet Alert
05/08/2023Buy Now0.27%Stephens & Co.
Mason Carrico41%
→ $30Reiterates → OverweightGet Alert
02/23/2023Buy Now13.64%Needham
Mike Matson57%
$33 → $34MaintainsBuyGet Alert
01/18/2023Buy NowRaymond James
Andrew Cooper54%
DowngradeOutperform → Market PerformGet Alert
01/05/2023Buy Now10.29%Scotiabank
Sung Ji Nam47%
→ $33Initiates → Sector OutperformGet Alert
11/04/2022Buy Now-26.47%Morgan Stanley
Tejas Savant50%
$23 → $22MaintainsUnderweightGet Alert
11/04/2022Buy Now-9.76%Raymond James
Andrew Cooper54%
$31 → $27MaintainsOutperformGet Alert
11/03/2022Buy Now10.29%Needham
Mike Matson57%
$31 → $33MaintainsBuyGet Alert
11/03/2022Buy Now16.98%SVB Leerink
Puneet Souda57%
$30 → $35MaintainsOutperformGet Alert
08/04/2022Buy Now3.61%Raymond James
Andrew Cooper54%
$30 → $31MaintainsOutperformGet Alert
08/03/2022Buy Now3.61%Needham
Mike Matson57%
$26 → $31MaintainsBuyGet Alert
05/05/2022Buy Now0.27%Stephens & Co.
Mason Carrico41%
$44 → $30MaintainsOverweightGet Alert
05/04/2022Buy Now-23.13%Morgan Stanley
Tejas Savant50%
$25 → $23MaintainsUnderweightGet Alert
05/04/2022Buy Now0.27%Raymond James
Andrew Cooper54%
$34 → $30MaintainsOutperformGet Alert
05/04/2022Buy Now-13.1%Needham
Mike Matson57%
$31 → $26MaintainsBuyGet Alert

FAQ

Q

What is the target price for Veracyte (VCYT) stock?

A

The latest price target for Veracyte (NASDAQ:VCYT) was reported by Stephens & Co. on March 26, 2025. The analyst firm set a price target for $45.00 expecting VCYT to rise to within 12 months (a possible 50.40% upside). 20 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Veracyte (VCYT)?

A

The latest analyst rating for Veracyte (NASDAQ:VCYT) was provided by Stephens & Co., and Veracyte reiterated their overweight rating.

Q

When was the last upgrade for Veracyte (VCYT)?

A

There is no last upgrade for Veracyte

Q

When was the last downgrade for Veracyte (VCYT)?

A

The last downgrade for Veracyte Inc happened on December 5, 2024 when Goldman Sachs changed their price target from $38 to $37 for Veracyte Inc.

Q

When is the next analyst rating going to be posted or updated for Veracyte (VCYT)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Veracyte, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Veracyte was filed on March 26, 2025 so you should expect the next rating to be made available sometime around March 26, 2026.

Q

Is the Analyst Rating Veracyte (VCYT) correct?

A

While ratings are subjective and will change, the latest Veracyte (VCYT) rating was a reiterated with a price target of $45.00 to $45.00. The current price Veracyte (VCYT) is trading at is $29.92, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch